Company intelligence / Profile preview

OBiO Technology

Shanghai, China

Ownership: Private
Employees: ~731
Development stage: Other

Overview

OBiO Technology provides end-to-end CRO/CDMO services for gene and cell therapies. It has supported over 25 IND approvals for clients globally (including eight FDA INDs), operates multiple GMP facilities in Shanghai, and offers proprietary vector development platforms. The company enables process development, analytical method development, clinical/commercial manufacturing of viral vectors/oncolytic viruses/cell therapies, plasmid construction, viral packaging services, recombinant protein/exosome production, and cell storage solutions. It is recognized for its cGMP-compliant operations and international reach with branches outside China.

Modalities: Gene therapyCell therapyRecombinant proteinExosome-based therapy
Industry: Contract Research Organization

Partnerships

CHINAGENEGE Medical

Beyond the preview

Go deeper on OBiO Technology.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on OBiO Technology.

Explore the full profile